<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04962022</url>
  </required_header>
  <id_info>
    <org_study_id>C4671015</org_study_id>
    <secondary_id>2021-003308-42</secondary_id>
    <nct_id>NCT04962022</nct_id>
  </id_info>
  <brief_title>Drug-Drug Interaction Study Assessing Effect of Itraconazole on PF-07321332/Ritonavir in Healthy Participants</brief_title>
  <official_title>COVID-19: A PHASE 1, OPEN-LABEL, FIXED SEQUENCE, 2-PERIOD CROSSOVER STUDY TO ESTIMATE THE EFFECT OF ITRACONAZOLE ON THE PHARMACOKINETICS OF PF-07321332/RITONAVIR IN HEALTHY PARTICIPANTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to estimate the effect of a strong inhibitor of CYP3A4&#xD;
      (itraconazole) on the pharmacokinetics (PK) of PF-07321332/ritonavir in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 20, 2021</start_date>
  <completion_date type="Actual">September 30, 2021</completion_date>
  <primary_completion_date type="Actual">September 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a Phase I, fixed sequnce, 2-period study to evaluate the effect of the strong CYP3A4 inhibitor, itraconazole, on the PK of PF-07321332 and ritonavir in healthy participants. A total of 12 healthy participants will be enrolled into this study.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of PF-07321332/ritonavir when administered alone</measure>
    <time_frame>Period 1 - Day 1 pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, and 48 hour post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of PF-07321332/ritonavir when administered with itraconazole</measure>
    <time_frame>Period 2 - Day 1 pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, and 72 hour post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of PF-07321332/ritonavir when administered alone</measure>
    <time_frame>Period 1 - Day 1 pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, and 48 hour post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of PF-07321332/ritonavir when administered with itraconazole</measure>
    <time_frame>Period 2 - Day 1 pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, and 72 hour post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)</measure>
    <time_frame>Up to Day 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Participants With Laboratory Abnormalities</measure>
    <time_frame>Up to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Participants With Vital Signs Abnormalities of PF-07321332/ritonavir</measure>
    <time_frame>Period 1 up to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Participants With Vital Signs Abnormalities of PF-07321332/ritonavir with itraconazole</measure>
    <time_frame>Period 2 up to Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Abnormalities in Physical Examination (PE)</measure>
    <time_frame>Screening</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Participants With Clinically Significant Change in Electrocardiogram (ECG) Findings of PF-07321332/ritonavir</measure>
    <time_frame>Period 1 up to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Participants with Clinically Significant ECG findings of PF-07321332/ritonavir with itraconazole</measure>
    <time_frame>Period 2 up to Day 9</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy Participant</condition>
  <arm_group>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07321332/ritonavir orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Itraconazole + PF-07321332/ritonavir orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-07321332/ritonavir</intervention_name>
    <description>Administered orally every 12 hours for days for a total of 5 doses from Day 1 through Day 3</description>
    <arm_group_label>Period 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Administered orally once daily for 8 days from Days 1 through 8</description>
    <arm_group_label>Period 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-07321332/ritonavir</intervention_name>
    <description>Administered orally BID for 3 day for a total on 5 doses starting on Day 4 through Day 6</description>
    <arm_group_label>Period 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female participants who are overtly healthy as determined by medical&#xD;
             evaluation including medical history, PE, laboratory tests, vital signs and standard&#xD;
             12 lead ECGs.&#xD;
&#xD;
          2. Participants who are willing and able to comply with all scheduled visits, treatment&#xD;
             plan, laboratory tests, lifestyle considerations, and other study procedures.&#xD;
&#xD;
          3. Female participants must have a negative pregnancy test.&#xD;
&#xD;
          4. BMI of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lb). -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Positive test result for SARS-CoV-2 infection at the time of Screening or Day -1.&#xD;
&#xD;
          2. Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or&#xD;
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,&#xD;
             seasonal allergies at the time of dosing).&#xD;
&#xD;
          3. Clinically relevant abnormalities requiring treatment (eg, acute myocardial&#xD;
             infarction, unstable ischemic conditions, evidence of ventricular dysfunction, serious&#xD;
             tachy or brady arrhythmias) or indicating serious underlying heart disease (eg,&#xD;
             prolonged PR interval, cardiomyopathy, heart failure greater than NYHA 1, underlying&#xD;
             structural heart disease, Wolff Parkinson-White syndrome).&#xD;
&#xD;
          4. Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).&#xD;
&#xD;
          5. History of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV,&#xD;
             HBsAg, or HCVAb. Hepatitis B vaccination is allowed.&#xD;
&#xD;
          6. Other medical or psychiatric condition including recent (within the past year) or&#xD;
             active suicidal ideation/behavior or laboratory abnormality or other conditions or&#xD;
             situations related to COVID-19 pandemic (eg, contact with positive case, residence, or&#xD;
             travel to an area with high incidence) that may increase the risk of study&#xD;
             participation or, in the investigator's judgment, make the participant inappropriate&#xD;
             for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brussels Clinical Research Unit</name>
      <address>
        <city>Brussels</city>
        <state>Bruxelles-capitale, RÃ©gion DE</state>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C4671015</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 10, 2021</study_first_submitted>
  <study_first_submitted_qc>July 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug-drug interaction</keyword>
  <keyword>Itraconazole</keyword>
  <keyword>CYP3A4 inhibitor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Itraconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

